Calyx plans to partner with BAMF Health on an initiative to speed the development of radioligand therapies and immune-oncology agents.
The two firms hope that the collaboration will address problems caused by "fragmented service ecosystems," they said.
The project prompting the partnership is an actinium-225 initiative; TerraPower Isotopes will supply the actinium-225 isotopes and BAMF will use its GE HealthCare (GEHC) StarGuide SPECT/CT system and its dosimetry expertise to further enhance the study and application of actinium-225 in radioligand and immune-oncology therapies.
